{
  "meta": {
    "title": "92_Community_Medicine_Aiims_2018",
    "url": "https://brainandscalpel.vercel.app/92-community-medicine-aiims-2018-798dcc38.html",
    "scrapedAt": "2025-11-30T12:58:36.297Z"
  },
  "questions": [
    {
      "text": "A patient from a North-Eastern state was diagnosed to have an infection with P. falciparum malaria. What is the most appropriate treatment for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Artemether plus lumefantrine"
        },
        {
          "id": 2,
          "text": "Sulfadoxine plus pyrimethamine"
        },
        {
          "id": 3,
          "text": "Choroquine"
        },
        {
          "id": 4,
          "text": "Mefloquine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most appropriate treatment for <em>Plasmodium falciparum</em> infection in North-Eastern states is<strong>&nbsp;artemether (20 mg) plus lumefantrine (120 mg).</strong></p>\n<p>As per National Vector Borne Disease Control Program (<strong>NVBDCP</strong>):&nbsp;</p>\n<ul>\n<li><em><strong>Plasmodium malariae:</strong></em>&nbsp;treat as <em>Plasmodium&nbsp;falciparum</em></li>\n<li><em><strong>Plasmodium ovale:</strong></em>&nbsp;treat as <em>Plasmodium&nbsp;</em>vivax</li>\n<li><strong>Severe and complicated malaria</strong></li>\n</ul>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -Initial parenteral treatment x 24-48 hr:&nbsp; quinine/artemether/artesunate/arteether</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -Oral treatment after 48 hrs-after parenteral quinine:&nbsp;quinine + doxycyclinex 7 days or quinine + clindamycin x 7 days (pregnancy and chidren&lt;8yrs)</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -After parenteral artemisinin derivates: in NE states: ACT -AL X 3 days+primaquine (day2), in other states: ACT-SPX 3 days+primaquine (day 2)&nbsp;</p>\n<ul>\n<li><strong>Chemoprophylaxis</strong></li>\n</ul>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Short-term, less than or equal to 6 weeks: Doxycycline OD (start one day before travel and continue for 4 weeks after return)</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Long-term, more than 6 weeks: mefloquine weekly (start 2 weeks before travel and 4 weeks after return).</p><hr><h3>Related Pearl: Treatment of Malaria</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>\n<p><strong> Drug of Choice</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Primaquine Dose</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. vivax malaria </strong></p>\n</td>\n<td>\n<p><strong>Chloroquine</strong> 25 mg/kg divided as:</p>\n<p>10mg/kg on day 1</p>\n<p>10mg/kg on day 2</p>\n<p>5mg/kg on day 3</p>\n</td>\n<td>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>P. falciparum malaria</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days&nbsp;</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.75mg/kg on day 2</p>\n<p>0.75mg/kg on day 2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mixed infection</strong></p>\n<p>North East</p>\n<p>In other states</p>\n</td>\n<td>\n<p><strong>ACT-AL</strong> for 3 days</p>\n<p><strong>ACT-SP</strong> for 3 days</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>0.25 mg/kg for 14 days</p>\n<p>0.25 mg/kg for 14 days</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Resistance to ACT/ Severe malaria </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Quinine </strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong> -</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. vivax</strong></p>\n</td>\n<td>\n<p><strong>Chloroquine </strong></p>\n</td>\n<td>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pregnancy</strong></p>\n<p><strong>P. falciparum</strong></p>\n</td>\n<td>\n<p>1<sup>st&nbsp;</sup>trimester: <strong>Quinine</strong></p>\n<p>2<sup>nd</sup> and 3<sup>rd</sup> trimester<strong>: Area specific ACT</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Contraindicated</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>ACT:&nbsp;</strong>artemisinin-based combination therapy</p>\n<p><strong>AL:</strong>&nbsp;artemether-lumefantrine</p>\n<p><strong>SP</strong>: Sulfadoxine-<wbr />Pyrimethamine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3511",
      "difficulty": "easy"
    },
    {
      "text": "Choose the correct order of steps of disaster management.",
      "choices": [
        {
          "id": 1,
          "text": "Disaster impact – Mitigation – Rehabilitation – Response"
        },
        {
          "id": 2,
          "text": "Disaster impact – Response– Rehabilitation – Mitigation"
        },
        {
          "id": 3,
          "text": "Rehabilitation – Response – Disaster Impact – Mitigation"
        },
        {
          "id": 4,
          "text": "Response – Disaster impact –  Mitigation – Rehabilitation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div class=\"page\" title=\"Page 10\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The correct sequence of steps is&nbsp;<strong>disaster impact &ndash; response &ndash; rehabilitation &ndash; mitigation.</strong></p>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a5076dc4b8ef40b3a0654ee868d6bb60x1280x1193.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4e20c82e300145009d9a00abf34003b3x1280x2179.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3491",
      "difficulty": "easy"
    },
    {
      "text": "Chi square test is used to test the significance of association between:",
      "choices": [
        {
          "id": 1,
          "text": "Age and serum cholesterol level"
        },
        {
          "id": 2,
          "text": "Heart rate and body mass index"
        },
        {
          "id": 3,
          "text": "Sex and type of cancer"
        },
        {
          "id": 4,
          "text": "Weight of a patient before and after a treatment"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Chi square test is a nonparametric test that assesses the significance of association between<strong> two qualitative variables</strong>.</p>\n<p>Among the given options, <strong>sex and type of cancer</strong> is the only pair of qualitative variables. Hence the answer.</p><hr><h3>Related Pearl: Tests of Significance</h3><p><strong>How to choose which test to use?</strong></p>\n<ul>\n<li>See the <strong>variable</strong>. Are the variables <strong>quantitative</strong> or <strong>qualitative</strong>?\n<ul>\n<li>If the variables are <strong>qualitative&nbsp;</strong>(<strong>nominal</strong>), then <strong>Chi square test</strong> is used.</li>\n<li>If the variables are <strong>quantitative</strong>, then see whether <strong>2 groups or more than 2 groups&nbsp;</strong>.\n<ul>\n<li>If <strong>2 groups </strong>are being tested, then <strong>T tests</strong> are used. In that, if the same group is tested before and after, paired T test is used. Otherwise, unpaired T test is used.</li>\n<li>If <strong>more than 2 groups</strong> are being tested, then use <strong>ANOVA</strong>.</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<p><strong>1. T Tests</strong></p>\n<ul>\n<li><strong>Unpaired t tests</strong>\n<ul>\n<li>Also known as the <strong>student&rsquo;s t test, independent t test, two-samples t test</strong>.</li>\n<li>It's the <strong>most commonly used t test</strong>&nbsp;and it tests the difference between two groups (the means of 2 groups)<strong> independent</strong> of each other<strong>&nbsp;</strong>and indicates how significant the differences are<strong>.</strong></li>\n</ul>\n</li>\n<li><strong>Paired t tests</strong>\n<ul>\n<li>\"Pairs <strong>before</strong>&nbsp;marriage are not the same <strong>after!\"</strong></li>\n<li>So remember the&nbsp;<strong>paired</strong> test is mainly used in the comparison of a&nbsp;<strong>before and after scenario</strong>&nbsp;</li>\n<li>Also known as<strong> correlated t test,</strong>&nbsp;<strong>dependent samples t test</strong>.</li>\n<li>It is mainly used on dependent samples.<strong>&nbsp;</strong>For example, the cholesterol level of a person before and after using a specific drug.</li>\n<li>It can also be used when you put the <strong>same condition</strong> under <strong>test</strong> <strong>using different items</strong> or things. For example, same crash safety tests for different cars.</li>\n</ul>\n</li>\n<li><strong>T scores</strong>&nbsp;\n<ul>\n<li>The t score is referred to as the <strong>ratio </strong>of<strong>&nbsp;</strong>the difference between two groups and the difference within the groups.</li>\n<li>The <strong>smaller </strong>the t score, the <strong>more similarity</strong> there is between two groups and vice versa.</li>\n</ul>\n</li>\n</ul>\n<p>&nbsp;</p>\n<p><strong>2</strong>. <strong>Analysis of Variance (ANOVA)</strong></p>\n<ul>\n<li>The analysis of variance test (<strong>ANOVA)</strong> is used to test the difference between two or usually<strong> more than two groups (means) </strong>and here the inferences are made by analyzing the variances.</li>\n</ul>\n<p>&nbsp;</p>\n<p><strong>3</strong>. <strong>Chi-Square Test</strong></p>\n<ul>\n<li>The <strong>Chi-Square test (&chi;<sup>2</sup>)</strong> is a <strong>non-parametric(non-numeric) test</strong> and it is used to test hypotheses in relation to <strong>nominal scale data or categorical data.</strong></li>\n<li>It is a <strong>test of proportions and associations.</strong></li>\n<li>A Chi-square distribution is usually<strong> positively skewed</strong> but it approaches a normal distribution as its degrees of freedom increases.</li>\n<li>If the <strong>frequency of any of the cells of the categorical table</strong> is&nbsp;<strong>&lt;5</strong>, then&nbsp;<strong>Fisher&rsquo;s exact test</strong> is used.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5217",
      "difficulty": "medium"
    },
    {
      "text": "Sample sizes of samples 1, 2 and 3 are 1000, 800, 600 respectively. The order of margin of error will be ____________.",
      "choices": [
        {
          "id": 1,
          "text": "3 >2>1"
        },
        {
          "id": 2,
          "text": "3>1>2"
        },
        {
          "id": 3,
          "text": "1>2>3"
        },
        {
          "id": 4,
          "text": "1=2=3"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Curve 1 has the least margin of error, followed by curve 2, and then curve 3. So the order is<strong> 3&gt;2&gt;1.</strong></p>\n<p>The image shows three normal distribution curves of different sample sizes, having the same mean but different standard deviations.</p>\n<p>As the sample size is decreasing, the peak decreases and the curve becomes more flat, implying a wider confidence of interval for the given mean.</p>\n<p>The <strong>width of the base</strong> of the curve is <strong>directly proportional to the margin of error.</strong> </p><hr><h3>Related Pearl: Normal Distribution</h3><p><strong>The normal distribution </strong>curve is the most <strong>common </strong>shape taken by<strong> continuous data </strong>distributions. It is also called <strong>bell curve </strong>(bell-shaped) or <strong>Gaussian distribution</strong> after mathematician Karl Friedrich Gauss.</p>\n<p>The following is an image of three different normal distribution curves.</p><img src=\"https://cdn1.dailyrounds.org/uploads/99fb903f13594e838e63dcee222ccc82x479x387.JPEG\" alt=\"Pearl Image\"><p>Salient features of the&nbsp;<strong>standard normal distribution</strong>:</p>\n<ul>\n<li>Defined by two parameters:&nbsp;the<strong>&nbsp;mean&nbsp;</strong>and the&nbsp;<strong>standard deviation</strong></li>\n<li>Has<strong> mean</strong> of<strong> 0</strong> and a<strong> standard deviation</strong> of<strong> 1</strong></li>\n<li><strong>Mean = median = mode</strong></li>\n<li><strong>Symmetric</strong>&nbsp;and have&nbsp;<strong>bell</strong>-shaped <strong>curves</strong>&nbsp;with a single peak</li>\n<li>Total<strong> area under the curve </strong>is<strong> 1</strong></li>\n<li><strong>Frequency of values</strong>&nbsp;is <strong>more around the center</strong> and <strong>less around the tails</strong></li>\n<li><strong>No skew </strong>in the curve</li>\n<li>Data like blood pressure, heights, IQ scores, etc. form a normal distribution</li>\n<li>The <strong>empirical rule</strong> of a normal distribution:\n<ul>\n<li>Approximately <strong>68%</strong> of the distribution falls within <strong>one</strong> standard deviation of the mean (<strong>mean &plusmn; 1 SD</strong>)</li>\n<li>Approximately <strong>95%</strong> of the distribution falls within <strong>two </strong>standard deviations of the mean (<strong>mean &plusmn; 2 SD</strong>)</li>\n<li>Approximately <strong>99.7%</strong> of the distribution falls within <strong>three </strong>standard deviations of the mean (<strong>mean &plusmn; 3 SD</strong>)</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/9b2acfa7a0024a73895e0113ce912fbcx1280x1219.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/32951ed1cda941f3bd7484d8e8e30c62.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5218",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a heat-sensitive indicator of vaccine viability?",
      "choices": [
        {
          "id": 1,
          "text": "e-VIN"
        },
        {
          "id": 2,
          "text": "Freeze indicator"
        },
        {
          "id": 3,
          "text": "Vaccine vial monitor"
        },
        {
          "id": 4,
          "text": "Fridge indicator"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Vaccine vial monitors (VVM)</strong> are the only heat-sensitive indicator of vaccine viability that are routinely used in vaccines throughout the supply chain.</p>\n<p>VVM records <strong>cumulative heat exposure</strong> through a <strong>gradual change in color</strong>. If the color of the<strong> inner square is the same or is darker than the outer</strong> circle, the vaccine has been exposed to too much temperature and should be <strong>discarded.</strong></p><hr><h3>Related Pearl: Vaccine Vial Monitors</h3><ul>\n<li><strong>Vaccine vial monitors</strong> are used to monitor heat exposure of vaccines.</li>\n<li>It is a chemical indicator that records the cumulative heat exposure through a gradual change in color.</li>\n<li>If the color of the <strong>inner square</strong> is the <strong>same color or darker</strong> than the <strong>outer circle</strong>, it indicates that the vaccine has been exposed to too much heat and it must be <strong>discarded</strong>.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3914a3eb19cf43ec9273112090e7b3f6x600x1199.JPEG\" alt=\"Pearl Image\"><ul>\n<li>Currently, there are <strong>four types</strong> of VVMs (VVM2, VVM7, VVM14, and VVM30). They are chosen to match the heat sensitivity of the vaccine.</li>\n<li>The VVM can be located on the label of the vaccine or on the neck or cap of the ampule/vial.</li>\n<li>VVMs also help in <strong>reduction of vaccine wastage</strong> by indicating which batch of vaccines can be used first.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5215",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is set up for health planning at the village level?",
      "choices": [
        {
          "id": 1,
          "text": "Panchayat Health Committee"
        },
        {
          "id": 2,
          "text": "Village Health Planning and Management Committee"
        },
        {
          "id": 3,
          "text": "Rogi Kalyan Samiti"
        },
        {
          "id": 4,
          "text": "Village Health Sanitation and Nutrition Committee"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Village Health Sanitation and Nutrition Committee (VHSNC)</strong> has been formed to take collective actions on issues related to health and its social determinants<strong> at the village level</strong> (local level community action).</p>\n<p>The committee is formed at the revenue village level and it should act as a sub-committee of the gram panchayat. It should have a minimum of 15 members and ASHA residing in the village shall be the member secretary and convener of the committee.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5216",
      "difficulty": "medium"
    },
    {
      "text": "You have gone to a subcenter as part of an audit. How many infants should be registered in a year with a health worker working there?",
      "choices": [
        {
          "id": 1,
          "text": "50"
        },
        {
          "id": 2,
          "text": "100"
        },
        {
          "id": 3,
          "text": "150"
        },
        {
          "id": 4,
          "text": "200"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>150</strong> infants should be registered in a subcentre per year.</p>\n<p><strong>Annual infant population = (total population) x (% infants in population or expected birth rate)</strong></p>\n<p>The <strong>percentage of infants in the population</strong>, or the <strong>expected birth rate</strong>, should be obtained from local data. If a specific local percentage is not available, it is estimated to be<strong> 3% of the total.</strong></p>\n<p>Total <strong>population in a subcenter</strong> is <strong>5000.</strong></p>\n<p>Here, <strong>annual infant population</strong> = 5000 &times; 3/100 = <strong>150</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5213",
      "difficulty": "hard"
    },
    {
      "text": "As per the national immunization schedule, which vaccines are indicated at the first visit for immunization of a 13-month-old baby who has not been previously immunized?",
      "choices": [
        {
          "id": 1,
          "text": "BCG, OPV 1st dose, Pentavalent 1st dose, Rota virus 1st dose"
        },
        {
          "id": 2,
          "text": "OPV 1st dose, Pentavalent 1st dose, Measles 1st dose"
        },
        {
          "id": 3,
          "text": "BCG, OPV 1st dose, Measles 1st dose"
        },
        {
          "id": 4,
          "text": "OPV 1st dose, DPT 1st dose, Measles 1st dose"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>DPT-1, OPV-1 and Measles 1st dose</strong> will be given to this child.</p>\n<p>BCG can only be given upto 1 years of age, according to the National Immunisation Schedule. BCG will not be given to this child, if the National Immunisation Schedule is followed.</p>\n<p>Please note that BCG can be given upto 5 years of age, as part of the catch-up immunization schedule, which is put forth by the Indian Academy of Paediatrics and that is not followed in government setups.</p>\n<p>OPV can be given till 5 years of age.</p>\n<p>Measles can be given till 5 years of age.</p>\n<p>DPT can be given till 7 years of age (with booster doses).</p><p>Pentavalent vaccine can be given only upto the age of 1 year.</p><p><strong>World Immunization Week</strong>, observed in the <strong>last week of April</strong>, aims to highlight the collective action needed and to promote the use of vaccines to protect people of all ages against disease. WHO collaborates globally to raise awareness and support governments in implementing quality immunization programs. The ultimate goal of World Immunization Week is for more people – and their communities – to be protected from vaccine-preventable diseases.</p><hr><h3>Related Pearl: National Immunization Schedule (India)</h3><table>\n<tbody>\n<tr>\n<td><strong>Vaccine</strong></td>\n<td><strong>When to give</strong></td>\n<td><strong>Dose</strong></td>\n<td><strong>Route</strong></td>\n<td><strong>Site</strong></td>\n</tr>\n<tr>\n<td colspan=\"5\"><strong>For Pregnant Women</strong></td>\n</tr>\n<tr>\n<td>Td-1</td>\n<td>\n<p>Early in pregnancy</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Upper arm</td>\n</tr>\n<tr>\n<td>Td-2</td>\n<td>\n<p>4 weeks after Td-1*</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Upper arm</td>\n</tr>\n<tr>\n<td>Td- Booster</td>\n<td>\n<p>If received 2 Td doses in a pregnancy <br />within the last 3 yrs*</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Upper arm</td>\n</tr>\n<tr>\n<td colspan=\"5\"><strong>For Infants</strong></td>\n</tr>\n<tr>\n<td>BCG</td>\n<td>\n<p>At birth or as early as possible until one year of age</p>\n</td>\n<td>0.1 mL (0.05 mL until<br />1 month<br />age)</td>\n<td>Intra-dermal</td>\n<td>Left upper arm</td>\n</tr>\n<tr>\n<td>Hepatitis B - Birth Dose</td>\n<td>\n<p>At birth or as early as possible within 24 hrs</p>\n</td>\n<td>0.5 mL</td>\n<td> Intra-muscular</td>\n<td>Antero-lateral side of mid-thigh</td>\n</tr>\n<tr>\n<td>OPV - 0</td>\n<td>\n<p>At birth or as early as possible within the first 15 days</p>\n</td>\n<td>2 drops</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>OPV-1, 2 &amp; 3</td>\n<td>\n<p>At 6 weeks, 10 weeks, &amp; 14 weeks (can be given until 5 years of age)</p>\n</td>\n<td>2 drops</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>Pentavalent 1, 2 &amp; 3</td>\n<td>\n<p>At 6 weeks, 10 weeks, &amp; 14 weeks (can be given until one year of age)</p>\n</td>\n<td>0.5 mL</td>\n<td>lntra·muscular</td>\n<td>Antero-lateral side of mid-thigh</td>\n</tr>\n<tr>\n<td>Rotavirus</td>\n<td>\n<p>At 6 weeks, 10 weeks, &amp; 14 weeks (can be given until one year of age)</p>\n</td>\n<td>5 drops</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>IPV</td>\n<td>\n<p>Two fractional doses at 6, 14 weeks </p>\n</td>\n<td>0.1 mL</td>\n<td>Intra-dermal two fractional dose</td>\n<td>Intra-dermal: right Upper arm (at 6, 14 weeks)<br /><br /></td>\n</tr>\n<tr>\n<td>\n<p>PCV</p>\n<p>(wherever applicable)</p>\n</td>\n<td>\n<p>At 6 weeks and 14 weeks; Booster at 9 completed months</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra·muscular</td>\n<td>Antero-lateral side of mid-thigh, right</td>\n</tr>\n<tr>\n<td>Measles/MR 1<sup>st</sup> Dose</td>\n<td>\n<p>9 completed months to 12 months<br />(Can be given till 5 years of age)</p>\n</td>\n<td>0.5ml</td>\n<td>Sub-cutaneous</td>\n<td>Right upper arm</td>\n</tr>\n<tr>\n<td>JE- 1**</td>\n<td>\n<p>9 completed months to 12 months</p>\n</td>\n<td>0.5 mL</td>\n<td>\n<p>Intramuscular(killed)/Subcutaneous (live attenuated)</p>\n</td>\n<td>\n<p>Anterolateral aspect of mid-thigh/Left upper arm </p>\n</td>\n</tr>\n<tr>\n<td>Vitamin A<br />(1st dose)</td>\n<td>\n<p>At 9 completed months with measles Rubella</p>\n</td>\n<td>1 mL (1 lakh IU)</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td colspan=\"5\"><strong>For Children </strong></td>\n</tr>\n<tr>\n<td>DPT booster-1</td>\n<td>\n<p>16–24 months</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Antero-lateral side of mid-thigh  </td>\n</tr>\n<tr>\n<td>Measles / MR 2<sup>nd </sup>dose</td>\n<td>\n<p>16–24 months</p>\n</td>\n<td>0.5 mL</td>\n<td>Sub-cutaneous</td>\n<td>Right upper arm  </td>\n</tr>\n<tr>\n<td>OPV booster</td>\n<td>\n<p>16–24 months</p>\n</td>\n<td>2 drops</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>JE-2</td>\n<td>\n<p>16–24 months</p>\n</td>\n<td>0.5 mL</td>\n<td>\n<p>Intramuscular (killed)/Subcutaneous (live attenuated)</p>\n</td>\n<td>Anterolateral aspect of mid-thigh/Left upper arm </td>\n</tr>\n<tr>\n<td>Vitamin A***<br />(2nd to 9<sup>th</sup> dose)</td>\n<td>\n<p>16–18 months, followed by one dose every 6 months up to the age of 5 years</p>\n</td>\n<td>2 mL (2 lakh IU)</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>DPT booster 2</td>\n<td>\n<p>5–6 years</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Upper arm</td>\n</tr>\n<tr>\n<td>Td</td>\n<td>10 years &amp; 16 years</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>\n<p>Upper arm</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Give Td-2 or booster doses before 36 weeks of pregnancy. However, give these even if more than 36 weeks have passed. Give Td to a woman in labor, if she has not previously received Td.</p>\n<p>**JE vaccine is introduced in select endemic districts after the campaigns. Intramuscular (killed inactivated) vaccine is gradually replacing the live attenuated vaccine. This change is because the killed vaccines are more effective and require fewer doses.</p>\n<p>***The 2nd to 9th doses of vitamin A can be administered to children 1–5 years old during biannual rounds, in collaboration with ICDS.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5214",
      "difficulty": "medium"
    },
    {
      "text": "Regarding the given box-whisker plot, the true statement is:",
      "choices": [
        {
          "id": 1,
          "text": "Mean > Median > Mode"
        },
        {
          "id": 2,
          "text": "Mode > Median > Mean"
        },
        {
          "id": 3,
          "text": "Mode = Mean = Median"
        },
        {
          "id": 4,
          "text": "Peaked symmetrical distribution"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given <strong>box-whisker plot</strong> represents a <strong>positively</strong> (or right) <strong>skewed</strong> distribution.&nbsp; In a positively skewed distribution, <strong>the mean &gt; median &gt; mode</strong>.</p>\n<p>To further understand and correlate the fact, have a look at the following images:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a8627ad901984d5ba73af62c9f117f17x650x1175.PNG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/61641c5825e04bdaab48c22de2284cc8x785x1452.PNG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Mean, Median, Mode in Different Distribution Shapes</h3><ul>\n<li>The relationship between the mean, median and mode depends upon the distribution.</li>\n<li>In a <strong>unimodal symmetrical </strong>distribution like a <strong>normal distribution</strong>, all the <strong>three measures</strong> are approximately the<strong> same</strong>, as shown in Figure (2) in the following image, i.e., <strong>mean = median = mode.</strong></li>\n<li>Figure (3) in the following image shows a <strong>positively skewed</strong> distribution in which the <strong>longer tail </strong>is towards the<strong> positive direction</strong>. In this, the mean will be larger than the median and mode, i.e., <strong>mean &gt; median &gt; mode.</strong></li>\n<li>Figure (1) in the following image shows a <strong>negatively skewed</strong> distribution in which the <strong>longer tail </strong>is towards the<strong> negative direction</strong>. In this, the mean will be smaller than the median, i.e., <strong>mean &lt; median &lt; mode.</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d79321686162499ca8b9174d58e8f7aex1280x2893.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p>Unimodal <strong>symmetrical distribution</strong></p>\n</td>\n<td>\n<p><strong>Mean = Median = Mode</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Positively (right) skewed</strong> distribution</p>\n</td>\n<td>\n<p><strong>Mean &gt; Median &gt; Mode</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Negatively (left) skewed</strong> distribution</p>\n</td>\n<td>\n<p><strong>Mean &lt; Median &lt; Mode</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li>As seen in the figures above, in any distribution curve, the <strong>mode </strong>is generally the<strong> highest point</strong>. The <strong>mean</strong> will be pulled up or down <strong>based </strong>on the<strong> values</strong> in the distribution. The <strong>median </strong>will lie<strong> between</strong> the <strong>mode</strong> and <strong>mean</strong> and <strong>divide</strong> the distribution in two<strong> equal halves</strong> under the curve.</li>\n<li>A <strong>bimodal distribution</strong> will have <strong>two high</strong> points as shown in the image below.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/25c3b8cb808949c2891e9d098cd1ab54x1280x1007.JPEG\" alt=\"Pearl Image\"><ul>\n<li>Mathematically, the relationship between mode, median and mean in <strong>asymmetrical</strong> distributions can be given as:<br /><strong>Mode = 3 median – 2 mean</strong> (or) <strong>Mean = ½ (3 median – mode).</strong></li>\n<li><strong>Outlier </strong>is the statistical term used for an <strong>observation </strong>or value that is<strong> very distant </strong>from<strong> other </strong>observations in the distribution.</li>\n<li>In a distribution with <strong>outliers</strong>, <strong>preferred </strong>measure of central tendency is the <strong>median</strong>.</li>\n<li><strong>Mode </strong>is <strong>least </strong>affected<strong> by outliers</strong> but <strong>mean </strong>is the <strong>most</strong> affected out of all the measures of location.</li>\n</ul><hr><h3>Related Pearl: Box and Whisker Plot</h3><ul>\n<li>A box and whisker plot is used to show <strong>variation in a set of data</strong>.</li>\n<li>They can summarize data from various sources and display it in a single graph.</li>\n<li>A box and whisker plot is usually based on <strong>median, quartiles and percentiles</strong>.</li>\n<li>It is also called a <strong>box plot.</strong></li>\n<li>In the box plot as shown in the image, a simple box is divided into two by the <strong>median value</strong>. Above and below it are the <strong>whiskers</strong>. The top and bottom ends of the whiskers are the <strong>highest and lowest value of that group</strong>.&nbsp;</li>\n</ul><ul>\n<li>A box plot can help in identifying <strong>outliers</strong> and the <strong>interquartile range (IQR), </strong>as shown in the image below.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/557efa950e5f407ca148010054728d60x314x146.PNG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/82d87a7d0288489b82120648f2753b90.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6182",
      "difficulty": "medium"
    },
    {
      "text": "A randomised control trial is being conducted in patients with direct inguinal hernia, to compare the outcomes of a new surgery 'A' and the gold standard surgery 'B'.\nThe p value of this trial is found to be 0.04. What can we conclude from this?",
      "choices": [
        {
          "id": 1,
          "text": "Type II error is small and we can accept the findings of the study"
        },
        {
          "id": 2,
          "text": "The probability of false negative conclusion that operation A is better than B is 4%"
        },
        {
          "id": 3,
          "text": "The power of the study to detect the difference between operation A and B is 96%"
        },
        {
          "id": 4,
          "text": "The probability of a false positive conclusion that operation A is better than B is 4%"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Since the <strong>p-value</strong> of the study is found to be<strong> 0.04</strong>, we can infer that the <strong>probability</strong> of a <strong>false positive </strong>conclusion that the operation A is better than B is <strong>4%.</strong></p>\n<p>In this scenario, the <strong><em>p</em> value is 0.04</strong> which makes it, by convention, <strong>statistically significant</strong>. We can reject the null hypothesis and <strong>accept</strong> the <strong>alternative</strong> hypothesis that operation <strong>A</strong> is <strong>better</strong> than operation <strong>B</strong>.</p><hr><h3>Related Pearl: Concepts in Hypothesis Testing</h3><p><strong>Probability value (</strong><em>p</em><strong> value)</strong></p>\n<ul>\n<li>A&nbsp;<strong>probability value</strong>&nbsp;is the&nbsp;<strong>probability of an outcome given the hypothesis</strong>.</li>\n<li>It is not the probability of the hypothesis given the outcome, although the probability of the given hypothesis is not ignored.</li>\n<li>If the&nbsp;<strong>probability of an outcome is sufficiently low</strong>, we have&nbsp;<strong>evidence that the hypothesis is false</strong>.</li>\n<li>It is also called the&nbsp;<em>p</em><strong> value</strong>.</li>\n</ul>\n<p><strong>The Null Hypothesis and Alternative Hypothesis</strong></p>\n<ul>\n<li>The <strong>hypothesis that an apparent effect or outcome is only due to chance is a null hypothesis</strong>.</li>\n<li>In other words, a null hypothesis is one where there is <strong>no difference between the specified sample and population</strong> and any observed difference is due to chance or some other error.</li>\n<li>A null hypothesis is represented by <strong>H<sub>0</sub></strong>.</li>\n<li>If the <strong>null hypothesis</strong> is <strong>rejected</strong> as false, then there is an <strong>alternative</strong> or <strong>experimental hypothesis (H<sub>A</sub>)</strong>, which is logically accepted.</li>\n</ul>\n<p><strong>Criterion or Significance Level</strong> <strong>(&alpha;) </strong></p>\n<ul>\n<li>If the probability value of an outcome is sufficiently low, then the null hypothesis is rejected.</li>\n<li>This <strong>point below which we would define the probability value as being low enough</strong> to reject the null hypothesis is called the <strong>criterion</strong> or <strong>significance level </strong>or<strong> &alpha; (alpha) level</strong>.</li>\n<li>When the null hypothesis is rejected, the effect or outcome is said to be <strong>statistically significant</strong>.</li>\n<li>By <strong>convention</strong> (but not always), the <strong>level of &alpha; is 0.05</strong>, i.e., if the probability value of an outcome is <strong>less than or equal to 0.05 (</strong><em>p</em><strong> value &le; 0.05)</strong>, then the null hypothesis is <strong>rejected</strong>.</li>\n<li>If it is <strong>greater than 0.05</strong>, then the null hypothesis is <strong>accepted</strong>.</li>\n<li>Although by convention the level of <strong>&alpha; is 0.05</strong>, it can be lower but cannot be any higher.</li>\n</ul>\n<p><strong>Type I Error</strong></p>\n<ul>\n<li>The interpretation of <strong><em>p</em> value &le; 0.05 </strong>is that an investigator can be 95% sure that the result was not obtained by chance.</li>\n<li>It also means that there is a 5% probability that the result was obtained by chance.</li>\n<li>From this, we can deduce that the <strong>null hypothesis might indeed be true even though we rejected it</strong>.</li>\n<li>This is <strong>a type I error</strong>. In other words, <strong>when an alternative hypothesis is accepted even when it is false and the null hypothesis is true</strong>, it is a <strong>type I error</strong> or <strong>false positive error</strong>.</li>\n<li>It is also called an <strong>alpha (&alpha;) error</strong> as it is <strong>related to the criterion &alpha;</strong>.</li>\n<li>The <strong>lower the &alpha; level</strong>, the <strong>lower the rate of a type I error</strong> being made.</li>\n<li>Thus, it can be said that <strong>&alpha; is the maximum tolerable probability that a type I error is being made</strong> and that the <strong>p value is the probability that a significant difference is declared when there is none</strong>.</li>\n</ul>\n<p><strong>Type II Error</strong></p>\n<ul>\n<li>The error that is made by <strong>rejecting an alternative hypothesis when it is true</strong> or <strong>failing to reject a null hypothesis when it is false</strong> is called a <strong>type II error</strong>.</li>\n<li>It is also called a <strong>false negative error </strong>and more commonly, as a <strong>beta (&beta;) error</strong>.</li>\n<li>If the null hypothesis is false, then the <strong>probability of a type II error</strong> is <strong>&beta;</strong>.</li>\n<li>The <strong>power of a statistical test</strong> is indicated by <strong>1&ndash;&beta;.</strong></li>\n</ul>\n<p><strong>Power of a Test</strong></p>\n<ul>\n<li>The <strong>power of a test</strong> is the <strong>ability</strong> of a statistical test to <strong>avoid a type II error</strong>, which depends on its <strong>ability to detect a false null hypothesis</strong>.</li>\n<li>It is <strong>equal to 1&ndash;&beta;</strong>, which is the <strong>probability that a false null hypothesis will be rejected</strong>.</li>\n<li>By <strong>convention</strong>, a test is required to have a <strong>power of 0.8</strong> (or a <strong>&beta; of 0.2</strong>) to be <strong>acceptable</strong>. This is to say that a study that has less than 80% chance of detecting a false null hypothesis is unacceptable.</li>\n<li><strong>Type I errors are easily reduced by reducing the criterion &alpha;</strong>.</li>\n<li>A <strong>test's power will increase</strong> in the following conditions:\n<ul>\n<li>If <strong>&alpha; increases</strong>, but this will increase the chance of a type I error.</li>\n<li>If the <strong>difference between </strong>the <strong>sample mean </strong>and<strong> hypothesized mean increases</strong>. This is also called <strong>effect size</strong>.</li>\n<li>If <strong>sampling error decreases</strong>.</li>\n<li>If the <strong>sample size (n) increases</strong>.</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2662",
      "difficulty": "medium"
    },
    {
      "text": "A large number of tests were done in series. Which of the following will be true?",
      "choices": [
        {
          "id": 1,
          "text": "Sensitivity and specificity will increase"
        },
        {
          "id": 2,
          "text": "Sensitivity will decrease, specificity will increase"
        },
        {
          "id": 3,
          "text": "Sensitivity and specificity will decrease"
        },
        {
          "id": 4,
          "text": "Sensitivity will increase, specificity will decrease"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>When a large number of tests are done in <strong>series</strong>, net&nbsp;<strong>sensitivity </strong>is<strong> decreased </strong>and net<strong> specificity </strong>is<strong> increased.</strong></p>\n<p>Screening tests are done in&nbsp;<strong>series&nbsp;</strong>when the result of the <strong>first test determines</strong> whether to run the <strong>second</strong> <strong>test</strong> or not. e.g., HIV screening is done using consecutive ELISA.</p>\n<p>Screening tests are done in <strong>parallel&nbsp;</strong>when the second test is <strong>independently performed</strong> regardless of what the first test result is. Both the tests are done at the same time. For e.g., In LFT, multiple tests are done together like SGOT, SGPT, total bilirubin, alkaline phosphatase, etc.</p>\n<p>Following are the trends that are observed while evaluating screening tests:</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Tests in Series</strong></td>\n<td><strong>Tests in parallel</strong></td>\n</tr>\n<tr>\n<td>Combined sensitivity</td>\n<td>Decreases</td>\n<td>Increases</td>\n</tr>\n<tr>\n<td>Combined specificity</td>\n<td>Increases</td>\n<td>Decreases</td>\n</tr>\n<tr>\n<td>Combined PPV</td>\n<td>Increases</td>\n<td>Decreases</td>\n</tr>\n<tr>\n<td>Combined NPV</td>\n<td>Decreases</td>\n<td>Increases&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6994",
      "difficulty": "medium"
    },
    {
      "text": "Blood bag is to be disposed in:",
      "choices": [
        {
          "id": 1,
          "text": "Red bin"
        },
        {
          "id": 2,
          "text": "Yellow bin"
        },
        {
          "id": 3,
          "text": "Blue bin"
        },
        {
          "id": 4,
          "text": "Black bin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Blood bag</strong> should be disposed off in the <strong>yellow bin.</strong></p><hr><h3>Related Pearl: Biomedical waste disposal</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><span><strong>&nbsp;<span> Yellow bag </span></strong><strong><span>(non-chlorinated)</span></strong><strong><span>&nbsp;</span>&nbsp;</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Type of Waste</p>\n</td>\n<td>&nbsp;Treatment and Disposal Options</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human anatomical waste</strong></p>\n<p><strong>Animal anatomical waste</strong></p>\n</td>\n<td>\n<p><strong>Incineration</strong>/Plasma pyrolysis/Deep Burial</p>\n</td>\n</tr>\n<tr>\n<td><strong>Soiled Waste: </strong>Items like dressings, cotton swabs, and plaster casts contaminated with blood and body fluids and bags containing residual discarded blood.</td>\n<td>\n<p><strong>Incineration</strong>/Plasma pyrolysis/Deep Burial</p>\n<p>or</p>\n<p>Autoclaving/Microwaving/ Hydroclaving</p>\n<p>Later - Shredding/mutilation</p>\n</td>\n</tr>\n<tr>\n<td>Discarded linen, mattresses, beddings contaminated with blood or body fluid,<strong> routine masks, and gowns</strong></td>\n<td>\n<p>Non- chlorinated chemical disinfection<br />followed by incineration or Plazma<br />Pyrolysis or for energy recovery.<br />In absence of the above facilities, shredding,&nbsp;mutilation, or a combination of&nbsp;sterilization and shredding is used.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Microbiology, biotechnology, clinical laboratory waste</strong></p>\n<p>(Autoclave safe plastic bags used)</p>\n<p><strong>Blood bags</strong>, laboratory<br />cultures, stocks or&nbsp;specimens of microorganisms,<br />live or&nbsp;attenuated vaccines,&nbsp;human and animal cell&nbsp;cultures used in&nbsp;research, industrial&nbsp;laboratories, production&nbsp;of biological, residual&nbsp;toxins, dishes, and&nbsp;devices used for&nbsp;cultures.</p>\n</td>\n<td>\n<p>Pre-treatment with nonchlorinated chemicals</p>\n<p>Later - Incineration</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Expired/discarded medicine, cytotoxic drugs</p>\n</td>\n<td>Incineration/plasma pyrolysis/ disposal in a secured landfill</td>\n</tr>\n<tr>\n<td>&nbsp;\n<p><strong>Chemical waste</strong></p>\n<p>Chemicals used in biological production&nbsp;and used or discarded<br />disinfectants.</p>\n</td>\n<td>\n<p>Disposal- incineration/plasma<br />pyrolysis</p>\n<p>Encapsulation-&nbsp;hazardous waste treatment, storage, and&nbsp;disposal facility.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Chemical liquid</strong>&nbsp;<strong>waste</strong> :<br />Liquid waste generated&nbsp;due to the use of chemicals&nbsp;in the production of<br />biological and used or&nbsp;<strong>discarded disinfectants,</strong>&nbsp;silver X-ray film<br />developing liquid,<br />discarded formalin,<br />infected <strong>secretions,</strong><br /><strong>aspirated body&nbsp;fluids</strong>,&nbsp;liquid from&nbsp;laboratories and floor&nbsp;washings, cleaning,&nbsp;house-keeping and<br />disinfecting activities&nbsp;etc.</p>\n<p>&nbsp;</p>\n</td>\n<td>After resource recovery, the chemical<br />liquid waste shall be pre-treated before&nbsp;mixing with other wastewater.&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><span><strong>&nbsp; Red&nbsp;bag (non-chlorinated)&nbsp;&nbsp;</strong></span></p>\n</td>\n</tr>\n<tr>\n<td><strong>&nbsp;Type of Waste</strong></td>\n<td>\n<p><strong>&nbsp;<span>Treatment and Disposal Options</span></strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Recyclable contaminated</strong> waste</p>\n<p>Contaminated waste tubing, bottles, intravenous tubes and sets, <strong>catheters,</strong> <strong>urine bags</strong>, syringes (without needles and fixed needle syringes with their needles cut), <strong>vacutainers with</strong> <strong>needles cut,</strong> and gloves.</p>\n</td>\n<td>\n<p><strong>Autoclaving/Microwaving/<br />Hydroclaving</strong></p>\n<p>Followed by Shredding/mutilation</p>\n<p>And later, Energy recovery/Plastics to diesel or fuel oil/road-making</p>\n<p>Not to be sent to landfill</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p><strong>&nbsp; White (translucent)&nbsp;&nbsp;<br />(puncture-proof, leak-proof containers)</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Type of Waste</strong></td>\n<td>\n<p><strong>Treatment and Disposal Options</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Waste Sharps including metals.</strong></p>\n<p>Needles, syringes with fixed needles, needles from needle tip cutter or burner, scalpels, blades, or any other <strong>contaminated sharp</strong> object that may cause puncture and cuts. This includes both used, discarded, and contaminated metal sharps</p>\n</td>\n<td>\n<p>Autoclaving/ Dry heat sterilization</p>\n<p>Followed by - <strong>Shredding/mutilation</strong>/<br />encapsulation</p>\n<p>Later by - Iron foundries/sanitary landfill/waste sharps</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p>&nbsp;<span><strong><span>&nbsp; Blue&nbsp;&nbsp;</span><br /></strong></span><span><strong><span>(Puncture proof and leak proof containers with blue colored marking)</span></strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Type of Waste&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Treatment and Disposal Options</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Glassware</strong></p>\n<p>Broken or discarded and contaminated glass including medicine <strong>vials</strong> and <strong>ampules except</strong> those containing <strong>cytotoxic</strong> waste.</p>\n<p><strong>Metallic body implants</strong></p>\n</td>\n<td>\n<p>Sodium hypochlorite/Autoclaving/<br />Microwaving/Hydroclaving</p>\n<p>Later - Recycling</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>&nbsp;Note: <strong>Ash</strong> from the <strong>incineration</strong> of biomedical waste shall be disposed of at a <strong>common hazardous waste treatment and disposal facility</strong>. However, it may also be disposed of in a <strong>municipal landfill</strong>, <strong>if</strong> the toxic metals in incineration ash are <strong>within</strong> the <strong>regulatory quantities</strong> as defined under the Hazardous Waste (Management and Handling and Transboundary Movement) Rules, 2008 as amended from time to time.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6998",
      "difficulty": "easy"
    },
    {
      "text": "Phase 1 of a clinical trial is done to test:",
      "choices": [
        {
          "id": 1,
          "text": "Safety"
        },
        {
          "id": 2,
          "text": "Efficacy"
        },
        {
          "id": 3,
          "text": "Dose range"
        },
        {
          "id": 4,
          "text": "Pharmacoeconomics"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The phase I of clinical trial is done to test Safety.</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7008",
      "difficulty": "medium"
    },
    {
      "text": "A child was brought to you with complaints of fever, malaise and a rash. You diagnose the child with measles. What is the recommended period of isolation for this disease?",
      "choices": [
        {
          "id": 1,
          "text": "From onset of rash to 3 days after rash"
        },
        {
          "id": 2,
          "text": "2 weeks before rash to 1 week after rash"
        },
        {
          "id": 3,
          "text": "From onset of rash to 5 days after rash"
        },
        {
          "id": 4,
          "text": "From catarrhal stage to 5 days after rash"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>isolation period</strong> for measles is from the <strong>catarrhal </strong>(prodromal) stage to <strong>5 </strong><strong>days after</strong> the onset of the <strong>rash</strong>. </p>\n<p>The <strong>period of communicability </strong>is approximately<strong> 4 days before and 5 days after</strong> the appearance of the rash. Isolation of the patient for a week from the onset of rash adequately covers the period of communicability.</p><hr><h3>Related Pearl: Periods of Isolation for Selected Diseases</h3><p><strong class=\"ng-binding\"> Periods of Isolation for Selected Diseases</strong></p>\n<div class=\"panel-body ng-scope\">\n<p class=\"ng-binding ng-scope\"> </p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Duration of Isolation</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Chickenpox</p>\n</td>\n<td>\n<p>Until all lesions are crusted – usually about 6 days after onset of rash.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Measles</p>\n</td>\n<td>\n<p>From the onset of symptoms (catarrhal stage) to 5 days after the appearance of the rash</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cholera</p>\n</td>\n<td>\n<p>Until 3 days of tetracycline therapy.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Diphtheria </p>\n</td>\n<td>\n<p>Until 48 hours of antibiotics.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Shigellosis and salmonellosis</p>\n</td>\n<td>\n<p>Until 3 consecutive negative stool cultures.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hepatitis A</p>\n</td>\n<td>\n<p>3 weeks.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Influenza</p>\n</td>\n<td>\n<p>3 days after onset.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Polio</p>\n</td>\n<td>\n<p>2 weeks in adult; 6 weeks in children.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tuberculosis (sputum +)</p>\n</td>\n<td>\n<p>Until 3 weeks of effective chemotherapy.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Herpes zoster</p>\n</td>\n<td>\n<p>6 days after onset of rash.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Mumps</p>\n</td>\n<td>\n<p>Until the swelling subsides.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Pertussis</p>\n</td>\n<td>\n<p>4 weeks or until paroxysms cease. </p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Meningococcal meningitis</p>\n</td>\n<td>\n<p>Until the first 24 hours of effective antibiotic therapy.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Streptococcal pharyngitis</p>\n</td>\n<td>\n<p>Until the first 6 hours of effective antibiotic therapy.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n</div><hr><h3>Related Pearl: Period of communicability of important diseases</h3><p> </p>\n<table>\n<tbody>\n<tr>\n<td>Disease</td>\n<td>Period of communicability</td>\n</tr>\n<tr>\n<td>Chicken pox</td>\n<td> 1-2 days before to 4-5 days after appearance of rash</td>\n</tr>\n<tr>\n<td>Hepatitis B</td>\n<td>One month before the appearance of Jaundice till the disappearance of HbsAg</td>\n</tr>\n<tr>\n<td>Measles</td>\n<td>4 days before to 5 days after appearance of rash</td>\n</tr>\n<tr>\n<td>Rubella</td>\n<td>7 days before to 7 days after the rash</td>\n</tr>\n<tr>\n<td>Mumps</td>\n<td>4-6 days before to 7 days after symptoms onset</td>\n</tr>\n<tr>\n<td>Pertussis</td>\n<td>7 days before to 3 weeks after the onset of paroxysms</td>\n</tr>\n<tr>\n<td>Diphtheria</td>\n<td>Up to 4 weeks after disease onset</td>\n</tr>\n<tr>\n<td>Meningococcal meningitis</td>\n<td>Till meningococci are absent from nasal/throat swabs</td>\n</tr>\n<tr>\n<td>Influenza</td>\n<td>1 to 2 days before and 1 to 2 days after onset of symptoms</td>\n</tr>\n<tr>\n<td>Tetanus</td>\n<td>Not communicable</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6995",
      "difficulty": "medium"
    },
    {
      "text": "BCG vaccine provides protection against which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Pulmonary TB"
        },
        {
          "id": 2,
          "text": "CNS and disseminated TB"
        },
        {
          "id": 3,
          "text": "Pulmonary and CNS TB"
        },
        {
          "id": 4,
          "text": "Pulmonary and skeletal TB"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>BCG</strong> vaccine provides protection against<strong> CNS and disseminated TB.</strong></p>\n<p>It does not prevent primary infection. More importantly, it does not prevent reactivation of latent pulmonary infection, the principal source of bacillary spread in the community. The impact of BCG vaccination on transmission of <em>mycobacterium tuberculosis</em> is therefore limited.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7006",
      "difficulty": "medium"
    },
    {
      "text": "In a community, there are usually 40-50 reported cases of dengue every week. This week, there were 48 reported cases. This would classify as:",
      "choices": [
        {
          "id": 1,
          "text": "Epidemic"
        },
        {
          "id": 2,
          "text": "Endemic"
        },
        {
          "id": 3,
          "text": "Sporadic"
        },
        {
          "id": 4,
          "text": "Outbreak"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given scenario is an example of<strong> </strong>an<strong> endemic disease</strong>.</p>\n<p><strong>Endemic</strong> diseases are those that have a <strong>constant</strong> presence and /or <strong>usual prevalence</strong> of a disease or infectious agent in a population <strong>within</strong> a <strong>geographic area</strong>.</p>\n<p><strong>Epidemic</strong> refers to an <strong>increase</strong>, often <strong>sudden</strong>, in the number of cases of a disease above what is normally expected in that population in that area. </p>\n<p><strong>Outbreak</strong> carries the same definition of an epidemic, but is often used for a more <strong>limited geographic</strong> <strong>area</strong>.</p>\n<p><strong>Sporadic</strong> diseases occur in a <strong>haphazard</strong> and <strong>irregular</strong> manner from time to time.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7005",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following vaccines has not been introduced to the immunization programme in India?",
      "choices": [
        {
          "id": 1,
          "text": "Adult Japanese encephalitis"
        },
        {
          "id": 2,
          "text": "Influenza"
        },
        {
          "id": 3,
          "text": "Measles-Rubella"
        },
        {
          "id": 4,
          "text": "Rotavirus"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Influenza vaccine (Flu shot) has not been introduced to the National Immunization Programme in India. </p>\n<p>The Influenza vaccine provides protection against <strong>viral flu</strong> caused by the <strong>influenza virus</strong>.</p>\n<p>Note: <strong>Bacterial</strong> Hemophilus influenzae type-b <strong>(Hib)</strong> vaccine is different from the <strong>viral</strong> influenza <strong>(Flu)</strong> vaccine. HiB is a part of the pentavalent vaccine.</p><p><strong>World Immunization Week</strong> is celebrated in the <strong>last week of April</strong>.</p>\n<p>The theme of the <strong>2022</strong> campaign was '<strong>Long Life for All'.</strong></p>\n<p>The theme of the <strong>2023</strong> campaign is<strong> 'The Big Catch-Up'.</strong></p>\n<p>The theme of<strong> 2024</strong> campaign is<strong> \"Humanly Possible: Immunization for All\".</strong></p><hr><h3>Related Pearl: National Immunization Schedule (India)</h3><table>\n<tbody>\n<tr>\n<td><strong>Vaccine</strong></td>\n<td><strong>When to give</strong></td>\n<td><strong>Dose</strong></td>\n<td><strong>Route</strong></td>\n<td><strong>Site</strong></td>\n</tr>\n<tr>\n<td colspan=\"5\"><strong>For Pregnant Women</strong></td>\n</tr>\n<tr>\n<td>Td-1</td>\n<td>\n<p>Early in pregnancy</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Upper arm</td>\n</tr>\n<tr>\n<td>Td-2</td>\n<td>\n<p>4 weeks after Td-1*</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Upper arm</td>\n</tr>\n<tr>\n<td>Td- Booster</td>\n<td>\n<p>If received 2 Td doses in a pregnancy <br />within the last 3 yrs*</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Upper arm</td>\n</tr>\n<tr>\n<td colspan=\"5\"><strong>For Infants</strong></td>\n</tr>\n<tr>\n<td>BCG</td>\n<td>\n<p>At birth or as early as possible until one year of age</p>\n</td>\n<td>0.1 mL (0.05 mL until<br />1 month<br />age)</td>\n<td>Intra-dermal</td>\n<td>Left upper arm</td>\n</tr>\n<tr>\n<td>Hepatitis B - Birth Dose</td>\n<td>\n<p>At birth or as early as possible within 24 hrs</p>\n</td>\n<td>0.5 mL</td>\n<td> Intra-muscular</td>\n<td>Antero-lateral side of mid-thigh</td>\n</tr>\n<tr>\n<td>OPV - 0</td>\n<td>\n<p>At birth or as early as possible within the first 15 days</p>\n</td>\n<td>2 drops</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>OPV-1, 2 &amp; 3</td>\n<td>\n<p>At 6 weeks, 10 weeks, &amp; 14 weeks (can be given until 5 years of age)</p>\n</td>\n<td>2 drops</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>Pentavalent 1, 2 &amp; 3</td>\n<td>\n<p>At 6 weeks, 10 weeks, &amp; 14 weeks (can be given until one year of age)</p>\n</td>\n<td>0.5 mL</td>\n<td>lntra·muscular</td>\n<td>Antero-lateral side of mid-thigh</td>\n</tr>\n<tr>\n<td>Rotavirus</td>\n<td>\n<p>At 6 weeks, 10 weeks, &amp; 14 weeks (can be given until one year of age)</p>\n</td>\n<td>5 drops</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>IPV</td>\n<td>\n<p>Two fractional doses at 6, 14 weeks </p>\n</td>\n<td>0.1 mL</td>\n<td>Intra-dermal two fractional dose</td>\n<td>Intra-dermal: right Upper arm (at 6, 14 weeks)<br /><br /></td>\n</tr>\n<tr>\n<td>\n<p>PCV</p>\n<p>(wherever applicable)</p>\n</td>\n<td>\n<p>At 6 weeks and 14 weeks; Booster at 9 completed months</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra·muscular</td>\n<td>Antero-lateral side of mid-thigh, right</td>\n</tr>\n<tr>\n<td>Measles/MR 1<sup>st</sup> Dose</td>\n<td>\n<p>9 completed months to 12 months<br />(Can be given till 5 years of age)</p>\n</td>\n<td>0.5ml</td>\n<td>Sub-cutaneous</td>\n<td>Right upper arm</td>\n</tr>\n<tr>\n<td>JE- 1**</td>\n<td>\n<p>9 completed months to 12 months</p>\n</td>\n<td>0.5 mL</td>\n<td>\n<p>Intramuscular(killed)/Subcutaneous (live attenuated)</p>\n</td>\n<td>\n<p>Anterolateral aspect of mid-thigh/Left upper arm </p>\n</td>\n</tr>\n<tr>\n<td>Vitamin A<br />(1st dose)</td>\n<td>\n<p>At 9 completed months with measles Rubella</p>\n</td>\n<td>1 mL (1 lakh IU)</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td colspan=\"5\"><strong>For Children </strong></td>\n</tr>\n<tr>\n<td>DPT booster-1</td>\n<td>\n<p>16–24 months</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Antero-lateral side of mid-thigh  </td>\n</tr>\n<tr>\n<td>Measles / MR 2<sup>nd </sup>dose</td>\n<td>\n<p>16–24 months</p>\n</td>\n<td>0.5 mL</td>\n<td>Sub-cutaneous</td>\n<td>Right upper arm  </td>\n</tr>\n<tr>\n<td>OPV booster</td>\n<td>\n<p>16–24 months</p>\n</td>\n<td>2 drops</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>JE-2</td>\n<td>\n<p>16–24 months</p>\n</td>\n<td>0.5 mL</td>\n<td>\n<p>Intramuscular (killed)/Subcutaneous (live attenuated)</p>\n</td>\n<td>Anterolateral aspect of mid-thigh/Left upper arm </td>\n</tr>\n<tr>\n<td>Vitamin A***<br />(2nd to 9<sup>th</sup> dose)</td>\n<td>\n<p>16–18 months, followed by one dose every 6 months up to the age of 5 years</p>\n</td>\n<td>2 mL (2 lakh IU)</td>\n<td>Oral</td>\n<td>Oral</td>\n</tr>\n<tr>\n<td>DPT booster 2</td>\n<td>\n<p>5–6 years</p>\n</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>Upper arm</td>\n</tr>\n<tr>\n<td>Td</td>\n<td>10 years &amp; 16 years</td>\n<td>0.5 mL</td>\n<td>Intra-muscular</td>\n<td>\n<p>Upper arm</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Give Td-2 or booster doses before 36 weeks of pregnancy. However, give these even if more than 36 weeks have passed. Give Td to a woman in labor, if she has not previously received Td.</p>\n<p>**JE vaccine is introduced in select endemic districts after the campaigns. Intramuscular (killed inactivated) vaccine is gradually replacing the live attenuated vaccine. This change is because the killed vaccines are more effective and require fewer doses.</p>\n<p>***The 2nd to 9th doses of vitamin A can be administered to children 1–5 years old during biannual rounds, in collaboration with ICDS.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7000",
      "difficulty": "medium"
    },
    {
      "text": "The life cycle of which of the following is depicted in the image below?",
      "choices": [
        {
          "id": 1,
          "text": "Japanese encephalitis"
        },
        {
          "id": 2,
          "text": "Zika virus"
        },
        {
          "id": 3,
          "text": "Rabies"
        },
        {
          "id": 4,
          "text": "Nipah virus"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given image depicts the life cycle of the <strong>Nipah virus</strong>.</p>\n<p>Nipah virus&nbsp;is an <strong>RNA</strong> virus that belongs to the family&nbsp;<strong>Paramyxoviridae</strong>, genus Henipavirus.&nbsp;It is a zoonotic virus that shows both animal-to-human (bats, pigs) and human-to-human transmission. The natural hosts are&nbsp;<strong>fruit bats</strong>&nbsp;of the Pteropodidae family.</p>\n<p>The clinical manifestations include asymptomatic subclinical&nbsp;infection, acute respiratory infection, and fatal encephalitis.&nbsp;There is <strong>no treatment</strong> or vaccine available for either people or animals. The primary treatment for humans is <strong>supportive</strong> care.</p>\n<p>Nipah virus is on the WHO list of <strong>Blueprint priority diseases</strong>.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/4bd6f0572d234ff7a7a1547f3143977c.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6999",
      "difficulty": "medium"
    },
    {
      "text": "While collecting blood for samples, you have spilled some on the floor. What would be the immediate next step?",
      "choices": [
        {
          "id": 1,
          "text": "Call the infection control team of the hospital"
        },
        {
          "id": 2,
          "text": "Mop it"
        },
        {
          "id": 3,
          "text": "Cover it with 1% sodium hypochlorite"
        },
        {
          "id": 4,
          "text": "Clean with absorbable material"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The immediate next step in this scenario is to clean the spilled blood with <strong>absorbable material.</strong></p>\n<p>This absorbable material is then discarded in the yellow bin.&nbsp;Following this,&nbsp;<strong>sodium hypochlorite</strong>&nbsp;solution is used to decontaminate the surface.&nbsp;The concentrations of sodium hypochlorite used are:&nbsp;</p>\n<ul>\n<li><strong>&lt; 10 mL</strong> blood spill -&nbsp;<strong>1:100</strong> dilution to decontaminate non-porous surfaces</li>\n<li><strong>&gt; 10 mL</strong> blood spill or <strong>culture</strong> spill - <strong>1:10</strong> dilution for the first application, followed by 1:100 dilution</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6997",
      "difficulty": "hard"
    },
    {
      "text": "The following drug packet is used in:",
      "choices": [
        {
          "id": 1,
          "text": "TB"
        },
        {
          "id": 2,
          "text": "Leprosy"
        },
        {
          "id": 3,
          "text": "Vaginal discharge"
        },
        {
          "id": 4,
          "text": "Gonorrhea"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given image shows the adult blister packet used in the treatment of&nbsp;<strong>leprosy.</strong></p><hr><h3>Related Pearl: WHO proposed Multi Drug Therapy (MDT) for the treatment of Leprosy</h3><p><strong>WHO proposed Multi-Drug Therapy (MDT) for the treatment of Leprosy</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Age group</strong></p>\n</td>\n<td>\n<p><strong>Drug</strong></p>\n</td>\n<td>\n<p><strong>Duration of Treatment</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adult</p>\n</td>\n<td>\n<p><strong>Rifampicin 600 mg</strong> once a month</p>\n<p>+</p>\n<p><strong>Clofazimine 300 mg</strong> once a month and <strong>50 mg daily</strong></p>\n<p>+</p>\n<p><strong>Dapsone 100 mg</strong> daily</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children (10&ndash;14 years)</p>\n</td>\n<td>\n<p>Rifampicin <strong>450 mg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>150 mg</strong> once a month and 50 mg <strong>alternate days</strong>.</p>\n<p>+</p>\n<p>Dapsone <strong>50 mg</strong> daily&nbsp;</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>\n</td>\n<td>&nbsp;\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children &lt;10 years old or &lt;40 kg</p>\n</td>\n<td>\n<p>Rifampicin <strong>10 mg/kg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>100mg</strong> once a month, 50mg <strong>twice weekly</strong></p>\n<p>+</p>\n<p>Dapsone <strong>2 mg/kg</strong> daily</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b1f7454268d74e0ebae486cbcdea6ee5.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7004",
      "difficulty": "easy"
    },
    {
      "text": "The symbol shown in the image depicts:",
      "choices": [
        {
          "id": 1,
          "text": "Cytotoxic waste"
        },
        {
          "id": 2,
          "text": "Biomedical waste"
        },
        {
          "id": 3,
          "text": "Radiation hazard"
        },
        {
          "id": 4,
          "text": "Biohazard"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>black</strong> <strong>propellers</strong> on a <strong>yellow background</strong> is the logo for <strong>radiation hazard.</strong></p>\n<p>This symbol is used to let everyone be aware of the hazard in an area where there is a source of radiation. This indicates the need for <strong>precautionary measures</strong> to avoid contamination.</p>\n<p>The other logos representing cytotoxic waste and biohazard are given in the image below.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/97ab3cc5fa0d4fe98a27003348ec9b15x1280x782.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e8ba401c8b254d4491889c91f66bf75a.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7003",
      "difficulty": "easy"
    },
    {
      "text": "The Mid Day Meal Programme aims to supplement:",
      "choices": [
        {
          "id": 1,
          "text": "1/2 protein and 1/3 calorie requirements"
        },
        {
          "id": 2,
          "text": "1/3 protein and 1/3 calorie requirements"
        },
        {
          "id": 3,
          "text": "1/2 protein and 1/2 calorie requirements"
        },
        {
          "id": 4,
          "text": "1/3 protein and 1/2 calorie requirements"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Under the<strong>&nbsp;Mid-Day Meal</strong>&nbsp;(MDM)&nbsp;<strong>scheme</strong>, supplementary nutrition provided must cover at least<strong>&nbsp;1/2 of total daily protein requirement and 1/3rd of total daily energy requirement</strong>&nbsp;of children in schools.</p>\n<p>The MDM scheme is also called&nbsp;<strong>School Lunch Programme</strong>&nbsp;and has been operational since 1961 in India. Currently, it functions under the broad coverage of the<strong>&nbsp;Minimum Needs Programme.</strong></p>\n<p>Some other principles of the MDM are:</p>\n<ul>\n<li>The meal provided under the MDM should only be a&nbsp;<strong>supplement</strong>&nbsp;and not a substitute for home diets.</li>\n<li>The<strong>&nbsp;cost </strong>of meals should be <strong>reasonably low.</strong></li>\n<li>The meal should be&nbsp;<strong>easy to cook</strong>&nbsp;in schools.</li>\n<li><strong>Locally available foods</strong>&nbsp;must be used, for as far as possible.</li>\n<li>The menu should be&nbsp;<strong>regularly changed</strong>&nbsp;to avoid monotony.</li>\n</ul>\n<p>Note: In September 2021, the Mid-Day Meal Scheme was renamed <strong>PM POSHAN</strong>&nbsp;or Pradhan Mantri Poshan Shakti Nirman.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7002",
      "difficulty": "easy"
    },
    {
      "text": "What test is used to check for freeze damage to vaccines?",
      "choices": [
        {
          "id": 1,
          "text": "Shake test"
        },
        {
          "id": 2,
          "text": "Schick test"
        },
        {
          "id": 3,
          "text": "Habel test"
        },
        {
          "id": 4,
          "text": "Tine test"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The freeze damage to vaccines is detected by <strong>Shake test. </strong></p>\n<ul>\n<li>A frozen vaccine is used as a&nbsp;<strong>control vial</strong>&nbsp;and the vial suspected to be damaged by freezing is taken as the&nbsp;<strong>test vial</strong>.</li>\n<li>Both are&nbsp;<strong>shaken after thawing</strong>&nbsp;and the&nbsp;<strong>rate of sedimentation</strong>&nbsp;is compared.</li>\n<li>If the rate of sedimentation in test vial is slower than the control vial, then it is usable and has not been damaged.</li>\n<li>Some of the most widely used&nbsp;vaccines&nbsp;are&nbsp;freeze-sensitive. Examples:&nbsp;Diphtheria, Tetanus, Pertussis, Liquid Haemophilus influenza type b (Hib), Hepatitis B.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7001",
      "difficulty": "easy"
    },
    {
      "text": "Study A(red) and Study B(blue) done in a given population yields two different distribution curves as shown below. Comparing both the curves, which of the following will be true?",
      "choices": [
        {
          "id": 1,
          "text": "Mean = mode = median"
        },
        {
          "id": 2,
          "text": "Mean = median, not equal to mode"
        },
        {
          "id": 3,
          "text": "Mean, median, mode not equal"
        },
        {
          "id": 4,
          "text": "Mode = median, not equal to mean"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>On comparing the 2 graphs, we can say&nbsp;<strong>mean=median</strong> for both study A and B but the <strong>mode </strong>is<strong> different</strong>.</p>\n<p>Study <strong>A</strong> is a <strong>unimodal symmetrical</strong> distribution, so <strong>mean=median=mode.</strong></p>\n<p>Study <strong>B</strong> is a <strong>bimodal</strong> distribution. Here, mean=median, but the curve has <strong>two highest points</strong>, therefore it has <strong>2 modes</strong>.&nbsp;</p><hr><h3>Related Pearl: Mean, Median, Mode in Different Distribution Shapes</h3><ul>\n<li>The relationship between the mean, median and mode depends upon the distribution.</li>\n<li>In a <strong>unimodal symmetrical </strong>distribution like a <strong>normal distribution</strong>, all the <strong>three measures</strong> are approximately the<strong> same</strong>, as shown in Figure (2) in the following image, i.e., <strong>mean = median = mode.</strong></li>\n<li>Figure (3) in the following image shows a <strong>positively skewed</strong> distribution in which the <strong>longer tail </strong>is towards the<strong> positive direction</strong>. In this, the mean will be larger than the median and mode, i.e., <strong>mean &gt; median &gt; mode.</strong></li>\n<li>Figure (1) in the following image shows a <strong>negatively skewed</strong> distribution in which the <strong>longer tail </strong>is towards the<strong> negative direction</strong>. In this, the mean will be smaller than the median, i.e., <strong>mean &lt; median &lt; mode.</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d79321686162499ca8b9174d58e8f7aex1280x2893.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p>Unimodal <strong>symmetrical distribution</strong></p>\n</td>\n<td>\n<p><strong>Mean = Median = Mode</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Positively (right) skewed</strong> distribution</p>\n</td>\n<td>\n<p><strong>Mean &gt; Median &gt; Mode</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Negatively (left) skewed</strong> distribution</p>\n</td>\n<td>\n<p><strong>Mean &lt; Median &lt; Mode</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li>As seen in the figures above, in any distribution curve, the <strong>mode </strong>is generally the<strong> highest point</strong>. The <strong>mean</strong> will be pulled up or down <strong>based </strong>on the<strong> values</strong> in the distribution. The <strong>median </strong>will lie<strong> between</strong> the <strong>mode</strong> and <strong>mean</strong> and <strong>divide</strong> the distribution in two<strong> equal halves</strong> under the curve.</li>\n<li>A <strong>bimodal distribution</strong> will have <strong>two high</strong> points as shown in the image below.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/25c3b8cb808949c2891e9d098cd1ab54x1280x1007.JPEG\" alt=\"Pearl Image\"><ul>\n<li>Mathematically, the relationship between mode, median and mean in <strong>asymmetrical</strong> distributions can be given as:<br /><strong>Mode = 3 median – 2 mean</strong> (or) <strong>Mean = ½ (3 median – mode).</strong></li>\n<li><strong>Outlier </strong>is the statistical term used for an <strong>observation </strong>or value that is<strong> very distant </strong>from<strong> other </strong>observations in the distribution.</li>\n<li>In a distribution with <strong>outliers</strong>, <strong>preferred </strong>measure of central tendency is the <strong>median</strong>.</li>\n<li><strong>Mode </strong>is <strong>least </strong>affected<strong> by outliers</strong> but <strong>mean </strong>is the <strong>most</strong> affected out of all the measures of location.</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/6ff5d7e687694e7084206608b28b8e89.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6992",
      "difficulty": "medium"
    },
    {
      "text": "A clinical trial was done between two groups to measure their blood pressure after treatment. Which of the following tests would be appropriate to use?",
      "choices": [
        {
          "id": 1,
          "text": "Paired t test"
        },
        {
          "id": 2,
          "text": "Unpaired t test"
        },
        {
          "id": 3,
          "text": "ANOVA"
        },
        {
          "id": 4,
          "text": "Chi-square test"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In the given scenario, two groups are being compared independent of each other. Hence,&nbsp;<strong>students&nbsp;t test/ unpaired</strong> t test should be used.</p>\n<p><strong>T tests</strong>&nbsp;are used if&nbsp;<strong>2 groups&nbsp;</strong>are being compared. If the same group is compared before and after, <strong>paired T test is used.</strong> Otherwise, unpaired T test is used.</p><hr><h3>Related Pearl: Tests of Significance</h3><p><strong>How to choose which test to use?</strong></p>\n<ul>\n<li>See the <strong>variable</strong>. Are the variables <strong>quantitative</strong> or <strong>qualitative</strong>?\n<ul>\n<li>If the variables are <strong>qualitative&nbsp;</strong>(<strong>nominal</strong>), then <strong>Chi square test</strong> is used.</li>\n<li>If the variables are <strong>quantitative</strong>, then see whether <strong>2 groups or more than 2 groups&nbsp;</strong>.\n<ul>\n<li>If <strong>2 groups </strong>are being tested, then <strong>T tests</strong> are used. In that, if the same group is tested before and after, paired T test is used. Otherwise, unpaired T test is used.</li>\n<li>If <strong>more than 2 groups</strong> are being tested, then use <strong>ANOVA</strong>.</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<p><strong>1. T Tests</strong></p>\n<ul>\n<li><strong>Unpaired t tests</strong>\n<ul>\n<li>Also known as the <strong>student&rsquo;s t test, independent t test, two-samples t test</strong>.</li>\n<li>It's the <strong>most commonly used t test</strong>&nbsp;and it tests the difference between two groups (the means of 2 groups)<strong> independent</strong> of each other<strong>&nbsp;</strong>and indicates how significant the differences are<strong>.</strong></li>\n</ul>\n</li>\n<li><strong>Paired t tests</strong>\n<ul>\n<li>\"Pairs <strong>before</strong>&nbsp;marriage are not the same <strong>after!\"</strong></li>\n<li>So remember the&nbsp;<strong>paired</strong> test is mainly used in the comparison of a&nbsp;<strong>before and after scenario</strong>&nbsp;</li>\n<li>Also known as<strong> correlated t test,</strong>&nbsp;<strong>dependent samples t test</strong>.</li>\n<li>It is mainly used on dependent samples.<strong>&nbsp;</strong>For example, the cholesterol level of a person before and after using a specific drug.</li>\n<li>It can also be used when you put the <strong>same condition</strong> under <strong>test</strong> <strong>using different items</strong> or things. For example, same crash safety tests for different cars.</li>\n</ul>\n</li>\n<li><strong>T scores</strong>&nbsp;\n<ul>\n<li>The t score is referred to as the <strong>ratio </strong>of<strong>&nbsp;</strong>the difference between two groups and the difference within the groups.</li>\n<li>The <strong>smaller </strong>the t score, the <strong>more similarity</strong> there is between two groups and vice versa.</li>\n</ul>\n</li>\n</ul>\n<p>&nbsp;</p>\n<p><strong>2</strong>. <strong>Analysis of Variance (ANOVA)</strong></p>\n<ul>\n<li>The analysis of variance test (<strong>ANOVA)</strong> is used to test the difference between two or usually<strong> more than two groups (means) </strong>and here the inferences are made by analyzing the variances.</li>\n</ul>\n<p>&nbsp;</p>\n<p><strong>3</strong>. <strong>Chi-Square Test</strong></p>\n<ul>\n<li>The <strong>Chi-Square test (&chi;<sup>2</sup>)</strong> is a <strong>non-parametric(non-numeric) test</strong> and it is used to test hypotheses in relation to <strong>nominal scale data or categorical data.</strong></li>\n<li>It is a <strong>test of proportions and associations.</strong></li>\n<li>A Chi-square distribution is usually<strong> positively skewed</strong> but it approaches a normal distribution as its degrees of freedom increases.</li>\n<li>If the <strong>frequency of any of the cells of the categorical table</strong> is&nbsp;<strong>&lt;5</strong>, then&nbsp;<strong>Fisher&rsquo;s exact test</strong> is used.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6993",
      "difficulty": "medium"
    },
    {
      "text": "Maternal mortality ratio (MMR) for a country is best given as __________",
      "choices": [
        {
          "id": 1,
          "text": "Maternal deaths per 100 live births"
        },
        {
          "id": 2,
          "text": "Maternal deaths per 10,000 live births"
        },
        {
          "id": 3,
          "text": "Maternal deaths per 100,000 live births"
        },
        {
          "id": 4,
          "text": "Maternal deaths per 1,000 live births"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Maternal mortality ratio</strong> is the number of<strong> maternal deaths </strong>in a given period<strong> per 100,000 live births</strong> during the same period.</p><hr><h3>Related Pearl: Maternal Mortality Ratio</h3><p><strong>Maternal death</strong> is defined as the death of a woman <strong>while pregnant or within 42 days of termination of pregnancy</strong>, irrespective of the duration and site of pregnancy, from <strong>any cause related to or aggravated by the pregnancy</strong> or its management but not from accidental or incidental causes.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/19493f9439a24b529b7a098cbbce594cx1280x644.JPEG\" alt=\"Pearl Image\"><p>The main global causes of maternal deaths are <strong>severe bleeding, indirect causes</strong> (anemia, malaria, heart diseases), <strong>infections, unsafe abortions, eclampsia, obstructed labor,</strong> and other direct causes like ectopic pregnancy, anesthesia-related complications, etc.</p>\n<p>In India, the most common causes of maternal deaths are hemorrhage (leading cause), sepsis, obstructed labor, hypertensive disorders, etc.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6996",
      "difficulty": "easy"
    },
    {
      "text": "SPIKES protocol is for:",
      "choices": [
        {
          "id": 1,
          "text": "Triage"
        },
        {
          "id": 2,
          "text": "Consent for study participation"
        },
        {
          "id": 3,
          "text": "Hospital infection control"
        },
        {
          "id": 4,
          "text": "Breaking bad news"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>SPIKES protocol is for <strong>breaking bad news.</strong></p>\n<p>Each letter represents a phase in the<strong> six-step</strong> <strong>sequence</strong>.</p>\n<ul>\n<li>S - setting</li>\n<li>P - perception</li>\n<li>I - invitation or information</li>\n<li>K - knowledge</li>\n<li>E - empathy</li>\n<li>S - summarizing or strategizing</li>\n</ul>\n<p><strong>Key components</strong> of the SPIKES strategy include:</p>\n<ul>\n<li>Demonstrating empathy</li>\n<li>Acknowledging and validating the patient's feelings</li>\n<li>Exploring the patient's understanding and acceptance of the bad news</li>\n<li>Providing information about possible interventions</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7009",
      "difficulty": "medium"
    },
    {
      "text": "According to the WHO Mental Health Gap Action Programme, which of the following is not included in the Mental Health Care Act, 2017?",
      "choices": [
        {
          "id": 1,
          "text": "Screening of family members"
        },
        {
          "id": 2,
          "text": "Mobilization of resources"
        },
        {
          "id": 3,
          "text": "Social support"
        },
        {
          "id": 4,
          "text": "Interpersonal therapy"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>According to the WHO Mental Health Gap Action Programme&nbsp;(<strong>mhGAP</strong>), screening of family members is not included in the Mental Health Care Act, 2017.</p>\n<p><strong>The Mental Healthcare Act of 2017&nbsp;</strong>has<strong>&nbsp;</strong>provisions that include:</p>\n<ul>\n<li>Rights of persons&nbsp;with mental illness to <strong>access</strong> <strong>health care</strong>, live without discrimination and enjoy <strong>confidentiality</strong>.</li>\n<li><strong>Advance directives&nbsp;</strong>to allow&nbsp;mentally ill people to make decisions about their treatment&nbsp;</li>\n<li>Procedures&nbsp;for admission, treatment (behavioral and <strong>interpersonal</strong> <strong>therapy</strong>, medications), and discharge&nbsp;</li>\n<li><strong>Decriminalizing</strong>&nbsp;<strong>suicide</strong> and prohibiting electroconvulsive therapy unless anesthesia is used</li>\n</ul>\n<p>These are achieved through the mobilization of resources to required areas, and by providing social support.</p><p>On October 10th, 2023, World Mental Health Day gives an opportunity for people and communities to come together under the banner of the subject \"Mental health is a universal human right\" The purpose is to expand awareness, raise consciousness, and motivate initiatives to develop and protect everyone's mental health, seeing it as a basic human right.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7010",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the appropriate schedule for the treatment of multi-drug resistant tuberculosis?",
      "choices": [
        {
          "id": 1,
          "text": "6 drugs for 4-6 months followed by 4 drugs for 12 months"
        },
        {
          "id": 2,
          "text": "7 drugs for 4-6 months followed by 4 drugs for 5 months"
        },
        {
          "id": 3,
          "text": "4 drugs for 4 months followed by  6 drugs for 10-12 months"
        },
        {
          "id": 4,
          "text": "5 drugs for 6 months followed by 4 drugs for 12 months"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The appropriate schedule for the treatment of multi-drug resistant tuberculosis<strong> (MDR-TB)</strong> is <strong>7 drugs</strong> for<strong> 4-6 months </strong>followed by<strong> 4 drugs</strong> for<strong> 5 months.</strong></p>\n<p>Note: Pearl 1720 has been updated according to NTEP 2021 guidelines.</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7007",
      "difficulty": "medium"
    },
    {
      "text": "The POCSO Act is related to which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Women empowerment"
        },
        {
          "id": 2,
          "text": "Human trafficking"
        },
        {
          "id": 3,
          "text": "Juvenile delinquency"
        },
        {
          "id": 4,
          "text": "Child sexual abuse"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The POCSO (Protection of Children from Sexual Offences) Act is related to <strong>child sexual abuse.</strong></p>\n<p>POCSO Act defines a child as any person <strong>below eighteen years </strong>of age. It defines different forms of sexual abuse, including <strong>penetrative</strong> and <strong>non-penetrative</strong> <strong>assault</strong>, as well as <strong>sexual harassment</strong> and <strong>pornography</strong>.</p>\n<p>The Act deems a sexual assault to be \"<strong>aggravated\"</strong>&nbsp;under certain circumstances, such as when the abused child is <strong>mentally ill</strong> or when the abuse is committed <strong>by a person in a position of trust or authority</strong> vis-&agrave;-vis the child, like a family member, police officer, teacher, or doctor.</p>\n<p>People who <strong>traffic children</strong> for sexual purposes are also punishable under the provisions relating to abetment in the Act.&nbsp;The Act prescribes stringent punishment graded as per the gravity of the offence, with a maximum term of rigorous imprisonment for life and a fine.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7011",
      "difficulty": "easy"
    },
    {
      "text": "Droplet precaution and isolation is to be done for all of the following conditions except:",
      "choices": [
        {
          "id": 1,
          "text": "Pertussis"
        },
        {
          "id": 2,
          "text": "Diptheria"
        },
        {
          "id": 3,
          "text": "Localized varicella zoster"
        },
        {
          "id": 4,
          "text": "Mycoplasma pneumonia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Droplet precaution and isolation is not done for localized varicella zoster, as it is only transmitted through direct contact.</p>\n<p>Varicella-zoster localized in the patient with an intact immune system with a lesion that can be contained/covered do not require droplet precaution. <strong>Disseminated varicella</strong> in any patient requires <strong>airborne</strong> and <strong>contact precautions.</strong></p>\n<p><strong>Diphtheria, pertussis, and mycoplasma </strong>are transmitted by droplets and hence <strong>require droplet precaution</strong> and isolation.</p>\n<p>Although patients are not contagious starting 48 hours after antibiotic therapy, droplet precautions are typically maintained until the completion of the antibiotic course and are culture-negative on two cultures taken 24 hours apart. Droplet precautions include the use of masks, gowns, gloves and protective eye gear when providing direct patient care.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7012",
      "difficulty": "medium"
    },
    {
      "text": "A patient presents with fever for 1 week, with abdominal distension, loss of appetite, and lymphadenopathy. There is a poor response to antibiotics and antimalarials. The Widal test is negative but  rk39 is positive. Which drug can be used in the treatment of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Liposomal Amphotericin B"
        },
        {
          "id": 2,
          "text": "Fluconazole"
        },
        {
          "id": 3,
          "text": "Linezolid"
        },
        {
          "id": 4,
          "text": "Bedaquiline"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div class=\"page\" title=\"Page 1882\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>This clinical scenario is suggestive of <strong>visceral leishmaniasis.</strong>&nbsp;This patient should be managed with <strong>liposomal amphotericin B.</strong></p>\n<p>This condition causes fever with rigor and chills associated with splenomegaly and hepatomegaly. Though lymphadenopathy is common in most endemic regions,&nbsp;it is rare&nbsp;in India.&nbsp;</p>\n<div class=\"page\" title=\"Page 1883\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>It is diagnosed by ELISA, indirect immunofluorescent antibody test (IFAT), and <strong>rk39 </strong>which detects <strong>antibodies </strong>to<strong>&nbsp;<em>Leishmania&nbsp;donovani</em>.</strong>&nbsp;</p>\n<p>The treatment is as follows:</p>\n<ul>\n<li>In most <strong>endemic regions</strong>:\n<ul>\n<li>Drug of choice - <strong>pentavalent antimonial</strong>&nbsp;(sodium stibogluconate or meglumine antimoniate)</li>\n<li>If it fails or is unavailable -&nbsp;amphotericin B&nbsp;</li>\n</ul>\n</li>\n</ul>\n<div class=\"page\" title=\"Page 1883\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>In <strong>India</strong> and <strong>Mediterranian</strong> countries, the drug of choice is <strong>liposomal</strong> <strong>AmB.</strong></li>\n<li>Other drugs - <strong>paromomycin</strong> and <strong>miltefosine</strong></li>\n</ul>\n<p>Option B: Fluconazole is an antifungal and is not useful in visceral leishmaniasis</p>\n<p>Option C: Linezolid is used in the treatment of MRSA&nbsp; and related infections.</p>\n<p>Option D: Bedaquiline is a newer anti-TB drug used in MDR-TB.&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7390",
      "difficulty": "easy"
    }
  ]
}